INTRODUCTION
Aberrant overexpression and malfunction of epidermal growth factor receptor (EGFR) have been observed in many cancers, of which proliferation, apoptosis, angiogenesis and metastasis were mediated by it [1, 2] . Upon EGF binding, EGFR forms hetero-or homo-dimers, leading to auto-phosphorylation and subsequently activating intracellular signaling transduction [3, 4] . Suppressing cancer EGFR signaling via anti-EGFR monoclonal antibody (mAb) blocking is, therefore, an attractive therapeutic strategy [4] .
Several mAbs-targeting cancer therapies have been approved by the Food and Drug Administration (FDA), including Erbitux (cetuximab) and Vectibix (panitumumab), which are used to treat colorectal cancer (CRC) and/or squamous cell carcinoma of the head and neck (SCCHN) by targeting EGFR [5, 6] ; Herceptin (trastuzumab) and pertuzumab, on the other hand, are used to treat gastric cancers by targeting EGFR2 [7, 8] . It has been reported that a combined treatment of cetuximab and radiotherapy of the SCCHN increased the survival rate from 36 to 45 % during the phase III clinical trial (p = 0.018).
Due to the economic consideration, however, use of Erbitux and Herceptin are limited in the less developed countries. This work focused on developing a substitute of Erbitux and Herceptin for a more affordable therapy option. The cetuximab biosimilar antibody APZ001, of which the protein sequence and biological functions bear similarity to cetuximab, was investigated, with its preclinical pharmacokinetics and pharmacovigilance evaluated.
EXPERIMENTAL

Reagents and drugs
Cetuximab (used as the positive control) was purchased from Merck Serono (lot: 219265, imported drug license: S201300041). Saline buffer (0.9 %) was purchased from Kelun Pharmaceutical Co. Inc. (lot: B120518 F1); pentobarbital sodium from Sinopharma Chemical Reagent Co. (#090205); ketamine hydrochloride from Shenyang Veterinary Medicines Co. (#20120501); serum quality control from Sysmex Inc. (#30010802); leucocyte hemolysin and basophil hemolysin from Sysmex Inc. (#R2021, #R2013). ELISA kits for IgA, IgE, IgG, and IgM were purchased from Fanbang Biotech Company (#20130402B) and were used according to the manufacturer's protocol. HRP-labeled secondary antibody was purchased from Jackson (#109-035-088) and TMB buffer was purchased from Neogen (#308176).
Quantification of serum antibody concentration
The serum concentration of cetuximab and APZ001 antibody was quantified by ELISA assay. 96-well plate coated with EGFR (50 μL, 0.25 μg/mL) was incubated at 4 ℃ overnight and was then washed with PBS.
The plate was blocked with BSA (2 %) at 25 ℃ for 2 h, after which the serum (100 μL) was added and incubated at 25 ℃ for 2 h. Subsequent to the PBS wash was HRP-labeled anti-human secondary antibody added and together incubated at 25 ℃ for 1 h. Results were visualized by TMB buffer (100 μL) and were then terminated by the Stop solution (50 μL). The absorbance was read by spectrophotometer (BioTek synergy H1) and was then processed and analyzed. 
Animal ethics and welfare
Pharmacokinetic studies
Thirty cynomolgus monkeys were randomly divided into five groups, with three males and three females in each group. Groups 1 to 3 received 7.5, 25 and 75 mg/mL of cetuximab biosimilar APZ001, respectively; group 4 received 75 mg/kg cetuximab for single pharmacokinetics analysis. 
Toxicity test
To test the toxicity of biosimilar APZ001, 50 cynomolgus monkeys were randomly divided into 5 groups with sexual equality: group A, negative control; group B, cetuximab positive control; group C, low concentration of APZ001 administered; group D, medium concentration of APZ001 administered; group E, high concentration of APZ001 administered. Drugs were injected intravenously weekly after the initial administration, of which the concentration was at 12 mL/kg (week 1); the drugs were then delivered at 7.5 mL/kg in the following experiment weeks (weeks 2-26).
Leukocyte differential count, bone marrow white blood cell classification, and immunoglobin protein analysis were also performed. The clinical condition of the animal was also recorded daily, including the symptoms, start time, severity, duration and reversibility of toxicity. Weeks 5 and 11 were set as the recovery periods.
Immunogenicity test
Blood samples were collected for immunogenicity examination during the chronic toxicity test. IgA, IgE, IgG and IgM were measured by ELISA a week before the administration and then at week 4, 13, 26, 31 and 37. Anti-drug antibody was determined a week before the administration and then at week 1, 2, 4, 6, 8, 10, 12, 20, 26, 28, 31 and 37. Leukocyte differential count, bone marrow white blood cell classification and immunoglobin protein analysis were performed to monitor the change in the immunogenic indicators.
Statistics analysis
All statistics analysis was processed with Excel software. Pairs of samples were compared by Ftest for equality of variances before using the ttest or U-test. Watson Figure 1 , p > 0.05) and was the same for the medium and high dose groups (p > 0.05, Table 1 ). The apparent volume of distribution (Vd) was also similar among the groups (p > 0.05, Table 1 ). Figure 2 shows the serum drug concentrations at each collection and the mean value of the group (n = 6). After four administrations, the drug accumulation ratio was 1.18 ± 0.07. Pharmacokinetic parameters of the initial and terminal administrations were not significantly statistically different. The serum drug concentration quickly reached a stable level upon repeated administration with no drug accumulation detected. In conclusion, the multiple administrations resulted in similar outcomes for both APZ001 and cetuximab (p > 0.05); the pharmacokinetic parameters also showed little difference (p > 0.05) during the following treatment, with relative bioavailability 116.9 %.
Toxicity
During the 26-week chronic drug administration, serum concentrations of APZ001 or cetuximab were tested ( Figure 3 ) and biomarkers for liver function and kidney function were analyzed afterwards. Chronic treatment with 38/24 mg/kg cetuximab, 38/24 mg/kg APZ001 or 120/75 mg/kg APZ001 increased the levels of albumin (ALB) and globulin (GCB) but decreased the A/G ratio, which recovered in the first recovery period. Several doses increased the levels of alanine aminotransferase (ALT), γ-glutamyltransferase (GGT), glutamic dehydrogenase (GLDH) and aspartate amino transferase (AST).
GLDH level returned to the baseline after two recovery periods, while other biomarkers only after one. Although the levels of liver biomarkers were found to increase, no significant changes were observed in liver weight or liver pathological examination. The 38/24 mg/kg dose cetuximab. and APZ001 groups exhibited similar changes in levels of GCB, ALB, A/G, ALT, GGT, GLDH and AST, indicating the similar liver toxicity effects.
The levels of other kidney function markers, including urine nitrite, glucose, protein, bilirubin, urobilinogen, acetone bodies and white cell count, did not exhibit abnormality in all tested groups. The medium-dose APZ001 and cetuximab groups showed similar side effects (e.g. skin toxicities), which did not fully recover. Changes in pathology and lesions to other organs were not observed, nor were abnormalities in the cynomolgus monkeys' body weight, rectal temperature, blood pressure, hematological coefficients and coagulation function. In conclusion, after the 6-month chronic toxicity test, various drug administrations did not cause significant changes, which included the rectal temperature, hematological and coagulation function, electrocardiogram, blood pressure, urea biomarkers, pathological examination, bone marrow and optical examination.
Immunogenicity
Serum immunoglobins IgA, IgE, IgG, and IgM were semi-quantified by ELISA according to the manufacturer's instructions with slight modification. Quantification of serum IgA showed the results at eight time points were significantly different from the blank serum control (Weeks 4, 13, 31, and 37; p < 0.05; Table 2 ), but were the same as the positive control cetuximab group. During the week 13, a potential systematic error caused the results acquired from the blank group different from the blank serum. Quantification of serum IgG showed the results collected at eleven time points were different from the corresponding blank serum controls (both positive and negative) ( Table 3 , p < 0.05), indicating a systematic error. Several results obtained from the medium-dose cetuximab group showed differences from the negative control group (Table 2, p < 0.05). Quantification of of IgE and IgM showed that the results were not significantly different from the negative groups. 
DISCUSSION
In addition to internal organ epithelium cells, EGFR was also reported to be expressed in the human skin within keratinocytes, the follicular epithelium, sweat and sebaceous glands and capillaries of the dermis, [11, 12] . Disturbance of EGFR signaling might result in hair follicle necrosis and alopecia [13, 14] . Minor side effects were reported in an earlier acute toxicity study, such as hair disorganization and partly alopecia in the cynomolgus monkeys [15] . Additionally, blocking EGFR function caused pathological reactions, such as skin inflammation, folliculitis and rash, due to the presence of EGFR in sebaceous glands [16] .
In this work, APZ001 was well metabolized and did not accumulate upon weekly i.v. administration for 6 months. In direct comparison with cetuximab, weekly administration of APZ001 did not induce any unprecedented adverse effects, while the predictable anti-EGFR-related side effects, such as skin rash, dehydration and liquid feces, occurred at acceptable levels and rates.
Administration of cetuximab and APZ001 increased the kidney weight and organ coefficient, but no pathological changes or lesions were observed. No apparent damage was observed in the kidneys upon pathological examination, nor were any hematological markers found. Previous study using fluorescent dye-labelled cetuximab also indicated moderate and acceptable toxicity to organs [17] . In addition, similar results were also reported by using a mixture of two biosimilars of cetuximab in the cynomolgus monkeys [18] .
Long-term drug administration led to the accumulation of drug in the circulation system, thus enhancing the kidney excretion activity to metabolize the excessive drug; the enhanced kidney function was maintained over a long course of time, leaving it impossible to recover in two recovery periods.
Slight to moderate skin toxicity side effects occurred to some cynomolgus monkeys. It was speculated that complete blocking of EGF-EGFR function in skin tissue might cause epidermal cell death occurring at a faster rate than cell growth, thus inducing skin toxicity. Many clinical studies of cetuximab have shown a direct correlation between the severity of rash and efficacy of treatment [19, 20] . Harandi and colleagues reported that patients with grade 3 rash had the highest survival rate during the treatment of cetuximab [21] . Administrations of APZ001 and cetuximab (38 and 24 mg/kg doses, respectively) induced similar toxicity reactions in skin and eyes, indicating that the chronic toxicity of APZ001 was within the safe range for human use.
CONCLUSION
The biosimilar, APZ001, showed similar properties to the positive control, cetuximab, including its pharmacokinetics, toxicokinetics, acute toxicity, chronic toxicity and immunogenicity toxicity. Thus, APZ001 antibody may show similar therapeutic effect to cetuximab.
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